The Efficacy & Safety of the UAS Immunotherapy Protocol
This study has been completed.
Information provided by (Responsible Party):
Frederick M. Schaffer, MD, United Allergy Services
First received: September 10, 2012
Last updated: October 3, 2012
Last verified: October 2012
Hypothesis: The UAS Immunotherapy protocol is efficacious and at least as efficacious as protocols described in the Allergy literature.
Perennial Allergic Rhinitis With Seasonal Variation
Other: allergen immunotherapy
||Observational Model: Case-Only
Time Perspective: Retrospective
||The Efficacy and Safety of the United Allergy Service (UAS) Immunotherapy Protocol
Primary Outcome Measures:
Secondary Outcome Measures:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||September 2012 (Final data collection date for primary outcome measure)
Patients will be assessed for efficacy of the immunotherapy protocol by completing Consented-IRB approved clinical, medication, quality of life survey questions comparing current status while on therapy in contrast to 12 months before the inception of therapy.
|Ages Eligible for Study:
||18 Years to 65 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Patients with allergic rhinitis pre and post immunotherapy (1 to 2 years).
- Allergic rhinitis between 18 and 65 years old who have chosen to undergo immunotherapy.
- No beta blocker use,
- no pregnancy,
- no systemic steroids,
- no severe asthma/copd,
- no severe collagen vascular disorders,
- no neoplastic or uncontrolled seizure activity,
- no previous anaphylaxis, no significant cardiovsacular disease.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01699659
|San Antonio, Texas, United States, 78216 |
United Allergy Services
||Frederick M Schaffer, M.D.
||United Allergy Services
No publications provided
||Frederick M. Schaffer, MD, Chief Medical Officer, United Allergy Services
History of Changes
|Other Study ID Numbers:
||UAS protocol #1, UAS protocol #1
|Study First Received:
||September 10, 2012
||October 3, 2012
||United States: Institutional Review Board
Keywords provided by United Allergy Services:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on June 30, 2015
Rhinitis, Allergic, Perennial
Immune System Diseases
Respiratory Tract Diseases